Dr Reddys Laboratories Q1FY20E Result Expectation

Consolidated revenue is expected to witness growth of 7.4% yoy on new launches in US (gSuboxone and gPropofol), growth in India and growth in CIS markets.

from India Infoline News Service https://ift.tt/2Oofws3